Clinical Tools & Resources
Explore our easy-to-navigate repository
Type:
Guideline
Source:
Canadian Association of Radiologists
Looking for information about clinical and diagnostic investigations appropriate for patients with possible cardiovascular related symptoms?
The Canadian Association of Radiologists supports your decision making by summarizing investigations indicated for cardiovascular related symptoms.
Type:
Guideline
Source:
College of Family Physicians of Canada
Searching for a guideline around lipid management in primary care?
The Patients, Experience, Evidence and Research (PEER) group created this guideline around lipids and the prevention and management of cardiovascular disease. Refer to this guideline when prescribing and managing lipid related therapy for your patients.
Tags: Cardiovascular Disease
Type:
Clinical Tool
Source:
Therapeutics Education Collaboration
Would you like an interactive tool you can use with your patients to walk through their risks and the impact of lifestyle and treatment options?
The Absolute CVD Risk/Benefit Calculator is designed to dynamically show how specific risk factors impact cardiovascular risk. Use this tool to help your patient understand the choices available to them and to guide shared decisions on how they can reduce their risks.
Tags: Cardiovascular Disease
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
How should you prioritize alcohol abstinence when managing atrial fibrillation?
This PEER Tool for Practice provides the latest information to help determine prioritization of alcohol abstinence when managing atrial fibrillation. Read this article to get the latest evidence on alcohol use and atrial fibrillation.
Tags: Cardiovascular Disease
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
Is it worthwhile using omega-3 derivatives, such as icosapent, when managing cardiovascular risk?
This PEER Tool for Practice summarizes the evidence on omega-3 derivatives and its impact on reducing cardiovascular risk. Read the article when looking for the evidence on icosapent and other omega-3 derivatives.
Tags: Cardiovascular Disease
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
Want to know what the PEER evidence group decided as the top 5 Tools for Practice articles in 2020?
The PEER evidence group summarizes the top Tools for Practice evidence summaries into one place. Read five different clinical topic summaries in one article.
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
What is the efficacy of Sodium Glucose Transport Protein-2 (SGLT2) inhibitors in patients with systolic heart failure?
This PEER Tool for Practice outlines the evidence on SGLT2 inhibitors in the treatment of systolic heart failure. Read this article to see the impact of SGLT2 inhibitors in heart failure.
Tags: Cardiovascular Disease
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
Is colchicine effective for secondary cardiovascular prevention?
This PEER Tool for Practice provides a review of cardiovascular prevention trials, and lists the major findings with respect to colchicine. Read this article if you have considered colchicine as a treatment for your cardiovascular patients.
Tags: Cardiovascular Disease
Type:
Patient Education
Source:
RxFiles
Looking for a patient handout regarding stopping Proton Pump Inhibitors? This patient handout describes the main reasons why a patient would consider stopping their proton pump inhibitor (PPI) medication, and provides tips for how patients can do so while minimizing risks of symptoms. The handout also provides general tips on coping with heartburn or reflex disease.
Tags: Cardiovascular Disease
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
Is exercise beneficial for patients with peripheral artery disease (PAD)?
This PEER Tool for Practice presents the available evidence that exercise therapy improves maximum walking distance and pain-free walking distance.
Type:
PEER Tools for Practice
Source:
PEER Tools for Practice
Which heart failure medications reduce death or hospitalization in patients?
This PEER Tool for Practice presents evidence from five systemic reviews in the last 5 years, that only mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce hospitalizations in patients with heart failure and ejection fraction of >40%. Other medications (CE inhibitors, ARBs, beta-blockers, and sacubitril-valsartan) were not found to reduce hospitalization or deaths. No medications were found to reduce mortality.
Tags: Cardiovascular Disease
We’re always expanding and updating our repository. Submit a resource for us to review for the Clinical Tools & Resources.
Share Your ResourceDid you find what you were looking for? Are we missing a key resource? We want to hear from you!
Share Your Feedback